Mizuho raised the firm’s price target on Harmony Biosciences (HRMY) to $36 from $35 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Holdings: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Harmony Biosciences Holdings: Strong Financial Performance and Positive Outlook Drive Buy Rating
- Harmony Biosciences raises FY25 revenue view to $845M-$865M from $820M-$860M
- Harmony Biosciences reports preliminary Q3 Wakix revenue $239M
- Harmony Biosciences price target lowered to $43 from $50 at UBS